Dr. Chiang Chi Leung - Clinical Oncology
Specialist in Clinical Oncology
Highlights
- MCHK RegisteredVerified
- 2 LocationsWong Chuk Hang · Jardine's Lookout
- Specialist in Clinical OncologyBachelor of Medicine and Bachelor of Surgery (MBChB) · Doctor of Medicine (MD) · Fellow of the Royal College of Radiologists · Medical degree 2004
- InsuranceBeing compiled｜See details
About
Dr. Chiang Chi Leung practises Clinical Oncology in Wong Chuk Hang and Jardine's Lookout, Hong Kong.
Education
Specialist in Clinical Oncology
- Bachelor of Medicine and Bachelor of Surgery (MBChB)Bachelor of Medicine and Bachelor of Surgery (MBChB)2004
- Doctor of Medicine (MD)Doctor of Medicine (MD)
- Fellow of the Royal College of RadiologistsFellow of the Royal College of Radiologists
- Fellow of the Hong Kong Academy of Medicine (Radiology)Fellow of the Hong Kong Academy of Medicine (Radiology)
Hong Kong Academy of Medicine fellowships
- FHKCRFellow, Hong Kong College of Radiologists
Source: Hong Kong Academy of Medicine Fellows Register, checked 12 Sep 2026
Locations
Insurance
Insurance plans being compiled
We're collecting insurance plan data per clinic. For confirmation, contact the clinic directly.
Are you Dr. Chiang Chi Leung? Claim page and update insurance →
FAQ
Is Dr. Chiang Chi Leung any good?
Dr. Chiang Chi Leung practises Clinical Oncology in Wong Chuk Hang and Jardine's Lookout, Hong Kong. Qualifications and registration come from the Hong Kong Medical Council. ok.med does not rate or rank doctors.
What does Dr. Chiang Chi Leung do?
Dr. Chiang Chi Leung practises in Clinical Oncology.
Where does Dr. Chiang Chi Leung practise?
Dr. Chiang Chi Leung practises at Gleneagles Hong Kong Hospital, Hong Kong Sanatorium & Hospital.
Are you Dr. Chiang Chi Leung? Claim this page to update and manage.
ClaimResearch and publications
51 papers · 12 most recent shown
Filter by paper topic
Topics come from medical classifications on these PubMed papers, not from the doctor's listed services.
- Compensatory Hypertrophy and Changes of Liver Function After Sequential Transarterial Chemoembolization, Stereotactic Body Radiation Therapy, and Immunotherapy (START-FIT) in Unresectable Hepatocellular Carcinoma.International journal of radiation oncology, biology, physics · 2026
- Complex-specific inhibitors for interrogating ATAC histone acetyltransferase complex.Nature chemical biology · 2026
- Cross-Platform Gene Signature to Predict Survival Outcomes for Nasopharyngeal Carcinoma.JCO precision oncology · 2026
- In Reply to Cao and Wang.International journal of radiation oncology, biology, physics · 2026
- Treatments of transarterial chemoembolization (TACE), stereotactic body radiotherapy (SBRT) and immunotherapy reshape the systemic tumor immune environment (STIE) in patients with unresectable hepatocellular carcinoma.Journal of the National Cancer Center · 2025
- Development and validation of ACTTOP: a prediction model for severe anticancer treatment toxicities in older patients with solid malignancy.Age and ageing · 2025
- Long-Term Outcome of Stereotactically Designed Hypofractionated Image Guided Radiation Therapy in Large, Unresectable Hepatocellular Carcinoma.Practical radiation oncology · 2025
- Formative evaluation of a mobile chat-based intervention (ChatEx) for promoting exercise behaviour in older cancer survivors.European journal of oncology nursing : the official journal of European Oncology Nursing Society · 2025
- Survival impact of conversion therapy for Barcelona Clinic Liver Cancer (BCLC) stage B and C hepatocellular carcinoma-a propensity score matching analysis.Hepatobiliary surgery and nutrition · 2025
- Functional Dose-Volume Analysis Based on a Novel Image Biomarker Derived From Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Predicting Poststereotactic Body Radiation Therapy Liver Function Preservation in Patients With Hepatocellular Carcinoma.Advances in radiation oncology · 2025
- Pre-existing CD95-based Temra immunity in patients with recurrent/metastatic nasopharyngeal carcinoma predicts response and hyperprogression to dual PD-L1 and TGFβ inhibition.Clinical and translational medicine · 2025
- Complete Response to Locoregional Therapy Plus Immunotherapy for Hepatocellular Carcinoma.JAMA oncology · 2024
Publication data comes from PubMed / Europe PMC and is matched automatically by name and affiliation. Every entry links to the source.
Elsewhere on the web
Hospital pages
These links are matched automatically by the doctor's name and are not confirmed by the doctor. Names repeat in Hong Kong — open a link to check.
For reference only. Not medical advice. Read full disclaimer